Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In comparing LCTC to BLO/BLOZF:
From Cannabix latest quarterly update:
Net loss for the period ended October 31, 2018 was $2,242,534
During the three-month period ended October 31, 2018, the Company incurred expenses of $2,277,678
The Company has not begun commercial sales of any of its technology holdings and nor has production occurred from activities on its resource properties and accordingly, the Company does not generate cash from operations. (Not one sale or source of revenue) The Company finances technology development by raising capital from equity markets. (That means constant dilution of shareholders)
If additional funds are required, the Company plans to raise additional capital primarily through the private placement of its equity securities.
As the Company does not currently generate revenue, cash balances will continue to decline as funds are utilized to conduct its operations, unless replenished by capital fundraising.
The Company’s operations to date have been financed by the issuance of its common shares. The Company continues to seek capital through various means including the issuance of equity and debt.
As of October 31, 2018 the Company had 101,632,732 common shares issued and outstanding. Plus an additional 5 million warrants outstanding, and 8,364,872 stock options outstanding
The Company expects to be involved in research and development to create several prototype marijuana breathalyzers and then performing extensive trial testing and conducting research studies with such devices prior to determining their commercial viability. This process may take several years and require significant financial resources without income. The Company expects these expenses to result in continuing operating losses for the foreseeable future.
Quarterly Net loss numbers: (2,242,534) (309,578) (477,322) (336,651) (357,394) (296,670) (1,210,131) (1,499,042)
Total loss over the last two years = $6,729,322
Market cap BLOZF = $110,779,678
Market cap LCTC = $12,638,615
BLOZF valued 8.7x
There is no way in hell that Cannabix should have a valuation over 8 times that of Lifeloc.
At absolute minimum, Lifeloc should be valued at half that of Cannabix.
That would equate to a $55 million market cap and a share price of $22.40.
I personally believe that Lifeloc will eventually see at least a valuation that is twice that of Cannabix. With human trials in the near future and progress being made with the SpinDx technology and marijuana breathalyzer I expect this to happen sooner rather than later.
Any comments are welcome!
Thanks
Interesting upwards price movement in LCTC and BLOZF towards the end of the day today. Let's see if we can get some follow through next week. Maybe a PR or news article is on its way.
LCTC is sitting right at the critical level of $5.65. We have not closed above this price level in months. We have bumped up against this level 6 times now so needless to say it's an important price area to get through.
CEO Dr. Wilkomm's response to questions:
Thank you for your continued interest and support for Lifeloc stock. With regards to your specific questions:
1. Are there any plans to provide a timeline for completion of the marijuana breathalyzer?
-We are not publicly releasing a time line as there are still uncertainties around the timing of development events. But I am very pleased that some of the other projects are wrapping up so that we can focus more resources on this very critical project.
2. We have previously talked about an uplisting to a major exchange and I'd like to know where things stand in regards to a NASDAQ listing.
-We do aspire to uplist to a major exchange and have assessed the cost and effort. For the short term, we are choosing to focus all resources (dollars, people and attention) on item 1.
3. We also talked about a possible stock split to increase the shares in the float as to bring in more long term investors. Can you provide any update in this regard?
-Being consistent with our aspiration to uplist, currently we do not have any plans for a stock split which would take our stock price below NASDAQ listing requirements.
4. Can Lifeloc make it a point to provide more PR's in 2019 as this will build some new investor awareness.
- Yes. We have worked hard to build a better story and it is appropriate now to take some more effort to tell that story.
This $5.65-$6.00 price level is important to break through.
Every time we get some buying interest, there seems to be a seller that comes back in with 1,000 share lots and continues to force downward pressure on the stock. With a public float this small the seller has to finish up at some point. I believe if this seller was not continually offering up shares, we would see a much higher stock price. I would like to get him out of the way and finished up so this thing can be properly priced with a market cap similar to BLOZF. ($40-$50 a share when compared to the market cap of BLOZF)
Questions sent to Dr. Wilkomm:
I would like to ask a couple questions so that I may be able to update investors and build some momentum in the stock price:
1. Are there any plans to provide a timeline for completion of the marijuana breathalyzer?
2. We have previously talked about an uplisting to a major exchange and I'd like to know where things stand in regards to a NASDAQ listing.
3. We also talked about a possible stock split to increase the shares in the float as to bring in more long term investors. Can you provide any update in this regard?
4. Can Lifeloc make it a point to provide more PR's in 2019 as this will build some new investor awareness.
Sales Forecasts of Alcohol Sensing Market Reveal Positive Outlook Through 2028
"There are very limited players in Alcohol Sensing market which includes AlcoPro Inc, BACKtrack Inc., Lifeloc Technologies, Abbot Laboratories, Alcohol Countermeasure Systems (International) Inc., Giner Labs, Honeywell International Inc., Asahi Kasei Corporation and Drägerwerk AG & Co. KGaA"
https://www.consultingindustry24.com/sales-forecasts-of-alcohol-sensing-market-reveal-positive-outlook-through-2028/
According to this recent article the Breath Analyzers Market is expected to Reach an Opportunity of over $4.5 Billion by the end of 2019.
"The world market for breath analyzers is forecasted to expand at a CAGR of 41.3% over the period between 2013 and 2019. The report also projects the international market for breath analyzers to reach a market valuation of around US$ 4,518.4 mn by the year 2019. The overall market was worth around US$ 402.1 mn in the year 2012."
Currently Lifeloc is capturing less than a half of a percent of this market.
It's go time Lifeloc. Figure out how to capture just 5% of this market and you will be Golden.
http://www.digitaljournal.com/pr/4072216
Looking at the current quarterly earnings report from Tilray TLRY:
Revenues of $10 Million vs. a market cap of $10 Billion
Net loss for the quarter was $18.7 million or $0.20 per share
Revenue increased to $10.0 (C$12.9) million, up 85.8% compared to the third quarter of last year. However this company has not had a profitable quarter since its inception. It has had a loss in the millions every year.
Lifeloc has Revenues of over $2 Million vs. a market cap of $10 Million
Lifeloc has shown 4 quarters of profitability and revenue growth. Granted the growth at TLRY is much higher.
I am confident that when Lifeloc starts seeing revenue from the marijuana breathalyzer sales, we are going to see some fireworks in this stock and a move similar to that of TLRY but even more explosive.
Comparison of Lifeloc vs. Cannabix and current state of development of the marijuana/cannabis breathalyzer:
Cannabix BLO/BLOZF:
Thus far testing has demonstrated the ability to isolate ?9-tetrahydrocannabinol (“THC”) and suppress background substrates and scientists are continuously working to improve resolving power.
The Company also reports that it has short listed 2 potential medical device development companies in order to develop the next version of the device as well as create multiple devices, that would be used for pilot testing.
This demonstrates the capability of the FAIMS device to isolate and detect THC from complex background matrix.
Recent testing with Beta 3.0 has shown the identification and first order separation of two key metabolites of ?9-tetrahydrocannabinol (“THC”), being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards. In addition, scientists have made significant progress towards using lower flow rates that will become important for user groups with poor lung function. Furthermore, engineers have been testing a new breath capture method that can hold THC breath samples in a stable manner for several days.
Lifeloc LCTC:
The marijuana breathalyzer took a step closer to realization with the detection of delta-9-THC (the psychoactive agent) captured from a vapor sample. The ability of our technology to detect delta-9-THC down to a concentration of 5 nanograms per milliliter has been demonstrated in our laboratories. Detection is accomplished through the SpinDx technology, licensed exclusively by Lifeloc Technologies for drugs of abuse from Sandia National Laboratory. More work is needed to convert this technology into a simple-to-operate device suitable for roadside testing. The next step is human testing of the collection and detection mechanism.
"We expect to start to realize benefits from the heavy product investments of the last few years.”
"Our vision is that Lifeloc becomes the world’s leading company in real-time alcohol and drug abuse detection and monitoring. To that effect, we continue to invest aggressively in research and development."
Lifeloc has focused product development on three specific fronts.
We will continue to push the bounds on our core portable breathalyzer business as we build a completely new breathalyzer platform with features that customers have demanded. Keeping our core business at the leading technical edge is critical as the core business allows us to fund our growth opportunities. This new breathalyzer platform is expected to begin limited production before the end of this year, with full scale production in the first quarter 2019.
We will build our alcohol monitoring business utilizing the Real-time Alcohol Detection and Recognition or R.A.D.A.R.® device product line acquired last year. R.A.D.A.R. devices are alcohol monitoring units with biometrics which can be used as a tool to supervise offenders as an alternative to incarceration. The upgraded R.A.D.A.R. device – with a more robust design and better communications – is expected to relaunch in the first quarter of 2019.
The marijuana breathalyzer took a step closer to realization with the detection of delta-9-THC (the psychoactive agent) captured from a vapor sample. The ability of our technology to detect delta-9-THC down to a concentration of 5 nanograms per milliliter has been demonstrated in our laboratories. Detection is accomplished through the SpinDx technology, licensed exclusively by Lifeloc Technologies for drugs of abuse from Sandia National Laboratory. More work is needed to convert this technology into a simple-to-operate device suitable for roadside testing. The next step is human testing of the collection and detection mechanism.
Progress! From Tonight's PR:
The marijuana breathalyzer took a step closer to realization with the detection of delta-9-THC (the psychoactive agent) captured from a vapor sample. The ability of our technology to detect delta-9-THC down to a concentration of 5 nanograms per milliliter has been demonstrated in our laboratories. Detection is accomplished through the SpinDx technology, licensed exclusively by Lifeloc Technologies for drugs of abuse from Sandia National Laboratory. More work is needed to convert this technology into a simple-to-operate device suitable for roadside testing. The next step is human testing of the collection and detection mechanism.
This is a giant step in the right direction! This puts us alongside Cannabix who is valued at 12 times that of Lifeloc.
Lifeloc has $1.08/share in cash
$3.35/share in total assets
$2.48/share in total stockholders equity
If you believe that Lifeloc at some point will have The SpinDx platform capable of real-time screening for a panel of high abuse drugs, with the ability to quickly and quantitatively measure very low concentrations of such drugs, including cocaine, methamphetamine and delta-9-THC (the primary psychoactive component of marijuana) down to concentrations of 5 nanograms per milliliter, then this stock at around this $4.00 level will wind up being a gift.
Regardless of any of that, this company still produces revenues of more than $8 Million/year which can not be said by too many other pink sheet/OTCBB stocks.
Obviously the game changer is the MMJ breathalyzer and the SpinDx coming to fruition.
Good luck to all involved!
Current market cap of Lifeloc sits right around $10 Million.
They anticipate a Billion dollar opportunity in regards to the marijuana breathalyzer within the next 10 years.
If LCTC does indeed create a working and reliable MMJ breathalyzer, I would expect with their distribution networks already in place, that a Billion in revenue could be reached within the first 2-3 years.
For Lifeloc to just reach a market cap of where Cannabix currently is, it would wind up trading at $52/share.
I could see Lifeloc trading well above this level with just an announcement indicating that a prototype is ready or some form of a timeline for completion.
If the revenues really start pouring in, This thing should trade upwards of $100/share. At $100/share, we would be trading at a market cap of $240 Million or so. Cannabix at one point had a market cap larger than this when it traded near $3/share last year. It's not impossible to think that with a $ Billion in revenues and a miniscule public float available that Lifeloc could trade upwards of $200-$300/share.
Of course this all rests on creating a working and reliable marijuana/cannabis breathalyzer but I have put my money where my mouth is and ready to see this thing start making some progress.
The most important statement in the entire report is as follows:
We remain committed to completing development of a marijuana breathalyzer, utilizing the SpinDx technology.
We really have no idea if Lifloc is further along than Cannabix in regards to completion of the marijuana breathalyzer but we know they are committed to completing it, which is very promising.
The articles, blogs, and reports have pretty much written off Lifeloc as a company that's still in the mix for the first MMJ breathalyzer. But at this point, we know that they are still viable and absolutely should be included.
Cannabix has over 100 million shares outstanding and they trade at $1.32. That puts a market cap over $130 Million. For a company without ever producing a dollar of revenue, no sales, no profits, dilution of shareholders every month, etc., it's all about the PR efforts from management and building that following. This is what Lifeloc has been missing from the beginning.
We also know from a 2018 Lifeloc presentation that they expect to build a billion dollar business out of the MMJ breathalyzer within 10 years:
"The opportunity is to build a $1 Billion business in 10 years."
I would expect Lifeloc to trade at least 1-2 x that of Cannabix with completion of their MMJ breathalyzer or even just an update for a timeline of completion.
We are sitting at just a $10.5 Million market cap. 1-2 x should put LCTC at a stock price of $53 to $106.
At some point, with a stock float this low, this is going to make a serious move higher. I'm convinced of that.
Good luck to all involved!
Highlights from the Quarterly Report:
Total Assets of $8.2 Million
Total Revenues over $2 Million
No Dilution to shareholders
Quarter over Quarter and Year over Year numbers are up across the board including Revenues, Net sales, and gross profit.
The SpinDx platform has the potential to revolutionize real-time screening for a panel of high abuse drugs, with the ability to quickly and quantitatively measure very low concentrations of such drugs, including cocaine, methamphetamine and others. We have detected delta-9-THC (the primary psychoactive component of marijuana) down to concentrations of 5 nanograms per milliliter in our laboratory. We remain committed to completing development of a marijuana breathalyzer, utilizing the SpinDx technology developed through our cooperative research and development agreement with Sandia National Laboratory.
The only reason that I know of that could possibly warrant Cannabix with a 12 x valuation over Lifeloc is that the management does a much better job with Utilizing PR firms, engaging social media, updating progress though news releases, and bullshitting investors. All of which has never been done by lifeloc.
That company dilutes shareholders on a monthly basis. As long as I have been following lifeloc, they have never added to the share count. Once.
Looks like some sector rotation out of Canadian cannabis names and looking to find a home somewhere.
For the love of Lifeloc, can you give us something that we can get excited about and share with potential investors that are looking to park some new funds.
Thanks!
Sounds Wonderful. You can have my vote for new Lifeloc CEO.
I'm not convinced the current CEO shares our vision.
They are sitting on a once in a lifetime opportunity and this stock is so thin that we could easily see a Taser or TLRY type move.
We had some good volume come in this week and it was all the buy side. Would have been great to see it continue into Thursday and Friday but we didn't even have a single trade on either of those days.
What I find a bit concerning is that the sell side continues to have shares on the offer in 1,000 lots every five or ten cents. With a public float so low, I have to wonder where all these sell side shares are coming from.
Let's see if we can manifest some news dealing with an update on the cannabis breathalyzer and get this seller done with and out of the way and get this thing moving upwards and onwards.
All the best!
As Canada has gone full adult recreational cannabis use, the demand for a reliable detection device is now more important than ever.
Directly from the Canadian Society of Forensic Science Drugs and Driving Committee (DDC):
Drug screening equipment shall have tetrahydrocannabinol (THC), cocaine, and methamphetamine as the target compounds for analysis.
SpinDx is a Detection platform for bodily fluid analysis for a panel of drugs and marijuana breathalyzer. SpinDX has been advanced to drugs of abuse through years of work under a cooperative research and development agreement between Lifeloc and Sandia. Feasibility of detection has already been demonstrated for very low levels of delta-9-THC, cocaine, and methamphetamine.
Dear Lifeloc,
You have exactly what Canada is looking for.
You have a multi billion dollar opportunity that is being handed to you on a golden platter.
Spend some cheese and hire the most talented people on the planet to help you get this thing to commercialization. The payoff will be tremendous. Get the people on your team that can make this happen.
There is nothing more important to you at this point.
This has to be where 90% of your focus needs to be.
Focus like a laser and let's see this happen.
Question:
Are there any companies/organizations public or private that have demonstrated detection of ?-9 THC down to 5 ng/ml with their cannabis/marijuana breathalyzer?
My quick research leads me to believe that Lifeloc is the only company that has been able to detect a quantity that low utilizing their SpinDX technology platform.
This company does not put out any horse shit so I'm pretty confident in their current detection levels. Just wondering if anyone has any insight into the other companies.
Thanks
From the Lifeloc 2018 Annual Shareholders meeting:
Investor Relations
Lifeloc seeks to broaden its investor base and market for its stock
Lifeloc presented company pitch at the April 2017 MicroCap Conference in
New York and the June 2017 LD MicroCap Conference in Los Angeles
Developing an investor relations mailing list
Looking to eventual uplisting to NASDAQ, with possible intermediate steps
Evaluating engagement of investor relations firms
Company will ramp up profile through social media and press releases
These are all absolutely phenomenal ideas!
I know because I was the one who has suggested every one of these to the CEO
However, I have yet to see a single one of these excellent plans of action fall into place. Any one of these could get this thing moving in the right direction. Let's make it happen Lifeloc. Start the engine or at least let's get the key in the ignition. It's GO TIME fellas!
Possible reason for the increased volume and move higher yesterday:
Lifeloc is a presenter at the upcoming Sidoti Conference
Sidoti & Company Fall 2018 Investor Conference
September 27th
NYC Grand Hyatt
8:00am - 5:00pm
Registration starts at 7:00
This entire float can be locked up at the current price level for right around a Million bucks. No other publicly traded traded stock that is over $1 is even close to those figures. If this company can ever get things moving, it could make a move similar to TLRY recently.
With any good news on the marijuana breathalyzer front and traders/investors scrambling for limited shares, a float lock down scenario could be amazing and like nothing we have ever seen. That's why I continue to hold and wait but to see it trading at an all time low is highly disappointing.
What I can't wrap my head around is how this company can be given a grant from the state of Colorado for $250,000 to develop a marijuana breathalyzer and barely use half of the grant over 4 years. This was free money. Your telling me you couldn't find a use for any of the remaining funds? This is absurd.
The management, including Dr. Wilkomm continues to let stock options expire worthless. Where is the drive to succeed with these guys?
As a shareholder from day 1, it's tough to find a silver lining here.
Share price sits at an all time low so I am completely on your side with your statement. Management and the new CEO have shown nothing, nada, zilch in regards to shareholders and stock price. This company continues to produce revenue, is profitable, owns a complete line of products, no dilution, cash in the bank, owns their building, and a miniscule float and sits at an all time low.
Mismanagement. Under the right guidance, this company could flourish!
Meanwhile BLOZF/BLO is valued at 15 times that of Lifeloc with no product, no revenue, no sales, and dilution of shareholders every month.
It may be time to replace some of the management and get this thing moving in the right direction. So much potential is being wasted.
TLRY has a market cap of over $20 Billion with revenues of $20 Million last year.
Lifeloc has a market cap of slightly less than $10 million with revenues over $8 million last year.
If Lifeloc were to make an announcement of a working marijuana breathalyzer, we would absolutely see a move similar to that of TLRY.
If Lifeloc were to have a market cap similar to that of TLRY, (here's where it gets fun), it would be worth $8,150/share.
I have to admit I have also been unimpressed with Lifeloc recently. When you are given a grant from the state of Colorado and 4 years to use it, I still can not grasp how they were unable to allocate funds to use even half of it.
This CEO has not really shown me anything since he has been at the helm. When I was communicating with Barry, the former CEO, he was able to answer questions in a timely manner and follow through with his promises. Wayne has not shown me yet he knows how to run a company. This sector has been screaming with growth and I have yet to see Lifeloc capitalize on any of it.
We are sitting at an all time low here while Cannabix (With no sales, no revenues, dilution every month, and a growing deficit) is valued at over 10 times.
It's time for some change over there at Lifeloc. I wonder what it would take to get Barry back in charge.
I am looking at the current share price - a 52 week low $4.80
The current market cap of less than $12 Million
Lack of investor awareness
No social media presence
What looks like minimal effort from the CEO to build any kind of momentum
Days and weeks without a trade
I have been here and in this stock from day 1 and have the first shares traded. Needless to say I have been a bit frustrated with the CEO and progress being made.
Since you did wind up attending the annual shareholder meeting, can you please provide me/us with any other positive news or insights from your visit?
How many other shareholders were there with you?
Could we expect a news release soon?
Was there any talk about a stock split or possible Nasdaq uplisting?
Anything further that you could provide us from attending the meeting would be great.
Thanks!
Spin Dx progress:
"SpinDx has demonstrated the ability to detect levels of THC down to 1 nanogram per milliliter under laboratory conditions. This includes resolving the psychoactive delta-9-THC from its inactive metabolites. Resolving the psychoactive levels from metabolites is an important step in establishing impairment. We believe this license agreement signifies the beginning of a relationship that will become material to the Company in the future. A prototype was built by Sandia under our Cooperative Research and Development Agreement and received in 2017, after which we commenced work on commercializing the device. We plan to continue and intensify these efforts in 2018."
They do have over $8 Million in Assets and close to $3 Million in Cash. They are a profitable revenue producing company, which most pink sheets and OTCBB can not say.
They are still making money and have not diluted shareholders. However, they have not shown shareholders too much in the way of growth.
"Our 2018 operating plan is focused on growing sales, increasing gross profits, and increasing research and development efforts on new products for long-term growth."
That's a great plan, however it's time for you to prove that's going to be the case.
I have recommended a stock split or uplisting to Nasdaq as two viable options to increase investor awareness but to no avail.
I'd really like to see some progress being made on all fronts.
I have not been impressed by any means in regards to the quarterly and annual reports. Liceloc sits in a sector that is screaming with growth and continues to fail to report numbers consistent with the sector momentum.
How does one receive a grant at no cost and not use the entire allotted funds? This blows my mind. Are you telling me they couldn't find a use for the $126,793 of grant funds that remain unused and are no longer available. This is absurd. They had 4 years. This is incompetence.
We have received no update in regards to the SpinDx technology, no investor awareness, no social media updates and nothing in regards to the marijuana breathalyzer. What are they doing over there?
We are sitting at a market cap of $12 Million while Cannabix remains over 10 times the value.
Barry Knott, the former CEO, was a man with a plan and knew what he was doing. I can not say the same for the current CEO, Mr. Wilkomm.
I am of the opinion that something needs to change over there.
Directly from the 2017 Lifeloc annual shareholder meeting:
Looking to eventual uplisting to NASDAQ
Evaluating engagement of investor relations firms
Updating website and social media pages
Company will more aggressively promote through press releases
As much as I also would like to see these come to fruition, I have yet to see progress made on any of these fronts.
I would love to continue to see the volume increase and price on the rise. When they do have a reliable device that begins testing, we are going to see this thing make some magic.
A second possible reason for today's move higher:
"The SpinDx, which Sandia has inked an agreement with Lifeloc to develop drug abuse technology, has proven that feasibility of detection has already been demonstrated for very low levels of delta-9-THC, cocaine, and methamphetamine."
The Canadian society for drug and driving committee is looking for exactly this type of testing equipment: In addition to testing for THC, the department requires the machines also be able to detect cocaine and methamphetamine as target compounds for analysis.
It could be that someone has taken notice that Lifeloc has the exact machine that Canada is looking for.
Directly from the Canadian Society of Forensic Science Drugs and Driving Committee (DDC):
Drug screening equipment shall have tetrahydrocannabinol (THC), cocaine, and methamphetamine as the target compounds for analysis. This drug screening equipment shall not analyze for any other target compounds. NOTE: The DDC may consider drug screening equipment for evaluation that has a subset of these target compounds for analysis. If so, evaluation procedures will be adjusted accordingly.
Drug screening equipment response to a mixture of drugs of interest shall also be tested.
SpinDX has been advanced to drugs of abuse through years of work under a cooperative research and development agreement between Lifeloc and Sandia. Feasibility of detection has already been demonstrated for very low levels of delta-9-THC, cocaine, and methamphetamine.
Current market cap comparisons:
BLO/BLOZF Cannabix - 97,576,354 shares outstanding x current price $1.82 = $177.5 Million
LCTC Lifeloc Technologies - 2,454,100 shares outstanding x current price $8.50 = $20.9 Million
Lifeloc is catching up but is still undervalued by at least 8 times
If Lifeloc were valued at a market cap equal to that of Cannabix, Lifeloc would be a $70 stock.
One possible reason for today's move higher on increased volume:
NHTSA is hosting a summit on March 15 to lead a national dialogue and call-to-action. NHTSA is bringing together key stakeholders—including safety partners; state and local elected officials; data and policy experts; law enforcement and criminal justice professionals; toxicologists and drug recognition experts—to join the U.S. DOT in setting a course of action and taking measurable steps to address the nation’s drugged-driving problem.
This summit is two days away and I would assume Lifeloc has a plan to attend and be a sponsor and/or presenter.
Current market cap comparisons:
BLO/BLOZF Cannabix - 97,576,354 shares outstanding x current price $1.90 = $185.4 Million
LCTC Lifeloc Technologies - 2,454,100 shares outstanding x current price $5.45 = $13.4 Million
Cannabix is valued at close to 14 times that of Lifeloc.
If Lifeloc were valued at a market cap equal to that of Cannabix, Lifeloc would be a $75 stock.
"We have reached out to NHTSA to find out more about the summit and are considering participating"
"The Colorado grant has run through the end date of the grant, funding will be reported in our annual report. The Colorado Office does not offer any evaluation of the results."
"We will continue to provide updates on the marijuana breathalyzer in our quarterly reports at a minimum."
This is the first time I have noticed that Lifeloc's products are all being sold on the Lifeloc online website. Previously, all of Lifeloc's products were being sold through a distributor.
https://www.lifeloc.com/drug-screen.html
Lifeloc has 64 various items that are being sold through its website all related to drug screening and testing.
They even sell the only on-site saliva test to be FDA cleared:
https://www.lifeloc.com/drug-screen/saliva-alcohol-tests/oratect-oral-fluid-drug-screen-device-6-panel-saliva-drug-test-fda-approved-case-of-25.html
This is a step forward and a move in the right direction for them.